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Summary
Background In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (EGFR)-targeted 
antibody cetuximab was added to standard chemotherapy in ﬁ rst-line treatment of advanced colorectal cancer with 
the aim of assessing eﬀ ect on overall survival.
Methods In this randomised controlled trial, patients who were ﬁ t for but had not received previous chemotherapy for 
advanced colorectal cancer were randomly assigned to oxaliplatin and ﬂ uoropyrimidine chemotherapy (arm A), the 
same combination plus cetuximab (arm B), or intermittent chemotherapy (arm C). The choice of ﬂ uoropyrimidine 
therapy (capecitabine or infused ﬂ uouroracil plus leucovorin) was decided before randomisation. Randomisation was 
done centrally (via telephone) by the MRC Clinical Trials Unit using minimisation. Treatment allocation was not 
masked. The comparison of arms A and C is described in a companion paper. Here, we present the comparison of 
arm A and B, for which the primary outcome was overall survival in patients with KRAS wild-type tumours. Analysis 
was by intention to treat. Further analyses with respect to NRAS, BRAF, and EGFR status were done. The trial is 
registered, ISRCTN27286448.
Findings 1630 patients were randomly assigned to treatment groups (815 to standard therapy and 815 to addition of 
cetuximab). Tumour samples from 1316 (81%) patients were used for somatic molecular analyses; 565 (43%) had KRAS 
mutations. In patients with KRAS wild-type tumours (arm A, n=367; arm B, n=362), overall survival did not diﬀ er 
between treatment groups (median survival 17·9 months [IQR 10·3–29·2] in the control group vs 17·0 months 
[9·4–30·1] in the cetuximab group; HR 1·04, 95% CI 0·87–1·23, p=0·67). Similarly, there was no eﬀ ect on progression-
free survival (8·6 months [IQR 5·0–12·5] in the control group vs 8·6 months [5·1–13·8] in the cetuximab group; 
HR 0·96, 0·82–1·12, p=0·60). Overall response rate increased from 57% (n=209) with chemotherapy alone to 64% 
(n=232) with addition of cetuximab (p=0·049). Grade 3 and higher skin and gastrointestinal toxic eﬀ ects were increased 
with cetuximab (14 vs 114 and 67 vs 97 patients in the control group vs the cetuximab group with KRAS wild-type 
tumours, respectively). Overall survival diﬀ ers by somatic mutation status irrespective of treatment received: BRAF 
mutant, 8·8 months (IQR 4·5–27·4); KRAS mutant, 14·4 months (8·5–24·0); all wild-type, 20·1 months (11·5–31·7). 
Interpretation This trial has not conﬁ rmed a beneﬁ t of addition of cetuximab to oxaliplatin-based chemotherapy in 
ﬁ rst-line treatment of patients with advanced colorectal cancer. Cetuximab increases response rate, with no evidence 
of beneﬁ t in progression-free or overall survival in KRAS wild-type patients or even in patients selected by additional 
mutational analysis of their tumours. The use of cetuximab in combination with oxaliplatin and capecitabine in ﬁ rst-
line chemotherapy in patients with widespread metastases cannot be recommended.
Funding Cancer Research UK, Cancer Research Wales, UK Medical Research Council, Merck KGgA.
Introduction
The introduction and biomarker reﬁ nement of treatments 
targeting the epidermal growth factor receptor (EGFR) 
has been one of the most promising developments in 
oncology treatment in the past 5 years. The beneﬁ t of 
EGFR tyrosine kinase inhibitors (geﬁ tinib and erlotinib) 
in lung cancer is limited to patients whose tumours 
contain a mutation at the drug-binding site in the ATP-
binding domain of the receptor, and has been seminal in 
the biomarker-deﬁ ned enrichment of the responsive 
populations.1,2 In colorectal cancer, no such mutations in 
EGFR occur, but clinical beneﬁ t has been shown with 
monoclonal antibodies, which bind to the extracellular 
receptor domain inhibiting ligand binding (notably 
epidermal growth factor, amphiregulin, and epiregulin) 
and receptor dimerisation.3 This clinical beneﬁ t, 
apparently limited to patients whose tumours contain no 
evidence of a mutation in KRAS, was ﬁ rst noted in non-
randomised studies4 and was subsequently conﬁ rmed in 
randomised trials of antibody monotherapy in patients 
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For the COIN trial protocol see 
http://www.ctu.mrc.ac.uk/
plugins/StudyDisplay/protocols/
COIN%20Protocol%20v5.1%20
October%202009.pdf
who were refractory to chemotherapy.5,6 This ﬁ nding is 
plausible because KRAS encodes a G protein, which is a 
key link in the signal transduction pathway (RAS–RAF–
MAP kinase) from receptor to nucleus, and the observed 
mutations result in constitutive activation of the pathway 
unlikely to be aﬀ ected by cell surface receptor binding. 
Other activating mutations such as those in BRAF and 
NRAS in colorectal cancers might have similar negative 
eﬀ ects on the eﬃ  cacy of EGFR-targeted therapy.7
We present the results of the Medical Research Council 
(MRC) COIN trial, which was the largest trial of the 
addition of an EGFR-targeted monoclonal antibody 
(cetuximab) to chemotherapy (in this case a regimen of 
oxaliplatin and a ﬂ uoropyrimidine) in the ﬁ rst-line 
treatment of advanced colorectal cancer, and in which the 
eﬀ ect was prospectively analysed primarily in relation to 
the mutational status of KRAS in tumour tissue, and 
secondarily in relation to the mutational status of BRAF, 
NRAS, and KRAS in tumour tissue. The COIN trial also 
assessed the eﬀ ect of preplanned treatment interruptions 
in oxaliplatin and ﬂ uoropyrimidine combination chemo-
therapy on overall survival; these results are reported in a 
companion paper.8
Methods
Trial design and participants
The COIN trial protocol is available on the MRC Clinical 
Trials Unit website. Patients were eligible to participate 
in the trial if they had given written informed consent, 
had histologically conﬁ rmed adenocarcinoma of the 
colon or rectum, inoperable metastatic or locoregional 
measurable disease, had received no previous 
chemotherapy for metastatic disease, and had WHO 
performance status 0–2 and good organ function.
COIN was approved by national research ethics 
committees in the UK and Ireland and both the Medicines 
and Healthcare Regulatory Agency and Irish Medicines 
Board. The trial was undertaken by the MRC Clinical 
Trials Unit, following the principles of Good Clinical 
Research Practice, and overseen by an independent trial 
steering committee. Conﬁ dential interim analyses were 
reviewed at least annually by an independent data 
monitoring committee.
Randomisation and masking
Patients were randomly assigned with minimisation by 
the MRC Clinical Trials Unit via telephone (1:1:1 ratio) to 
receive continuous chemotherapy (control, arm A) or 
one of two research interventions: continuous 
chemotherapy plus cetuximab (arm B) or intermittent 
chemotherapy (arm C; ﬁ gure 1). The minimisation 
factors were hospital, WHO performance status, 
chemotherapy regimen, previous adjuvant chemotherapy, 
liver metastases, and peritoneal metastases. Treatment 
allocation was not masked. The arm A versus B results 
are reported in this paper and the arm A versus C results 
are reported separately.8
Procedures
Oncologists chose between two chemotherapy regimens 
according to local hospital policy or patient preference: 
oxaliplatin plus capecitabine, or oxaliplatin plus 
ﬂ uorouracil and folinic acid. Oxaliplatin plus capecitabine 
was given as a 3-weekly regimen of intravenous 
oxaliplatin 130 mg/m² over 2 h followed by oral 
capecitabine twice a day for 2 weeks. The dose of 
capecitabine was 1000 mg/m² orally twice a day, but was 
reduced to 850 mg/m² twice a day in a protocol 
amendment for patients in arm B only after 1775 (73%) 
patients had been randomly assigned to all groups, when 
an analysis of toxic eﬀ ects showed that the rate of grade 3 
or 4 diarrhoea was higher than expected (30%).9 
Oxaliplatin plus ﬂ uorouracil and folinic acid was given 
as a 2-weekly regimen of intravenous L-folinic acid 
175 mg or D,L-folinic acid 350 mg over 2 h given 
concurrently with oxaliplatin 85 mg/m² over 2 h, 
followed by intravenous bolus ﬂ uorouracil 400 mg/m² 
then  ﬂ uorouracil 2400 mg/m² infusion over 46 h 
administered via an ambulatory pump and a central 
venous line. In arm B, cetuximab was given as an initial 
intravenous dose of 400 mg/m² over 2 h and subsequently 
at 250 mg/m² over 1 h once a week. Treatment was 
continued until disease progression, development of 
cumulative toxic eﬀ ects, or patient choice. Patients were 
allowed to discontinue one or more agents within the 
regimen as a result of toxic eﬀ ects, while continuing on 
the remaining agent or agents.
CT scans were done within 4 weeks before start of 
treatment, and were repeated every 12 weeks and assessed 
on the basis of RECIST (version 1.0) criteria.10 Because 
overall survival was the primary outcome measure of the 
trial, responses were not conﬁ rmed by repeat scans and 
external radiological review was not undertaken. 
Symptoms were scored with National Cancer Institute 
Common Terminology Criteria for Adverse Events 
(version 3.0).11 Serious adverse events and deaths, together 
with an assessment of causality, were continuously 
reported and assessed by an expert practising oncologist 
on behalf of the MRC.
In view of the emerging consensus that EGFR 
immunohistochemistry was not a reliable predictor of 
response to EGFR-targeted therapy,12 all patients 
irrespective of EGFR status were eligible for the COIN 
trial. However, all patients were asked to provide a 
tumour sample for future analysis of EGFR status. 
Consultation with the UK Human Tissue Authority and 
the research ethics committee concluded that the KRAS 
test could be done on all patients in addition to the EGFR 
test. Patients were also asked to provide additional 
consent for future bowel cancer research. Research staﬀ  
at randomising sites requested patients’ tumour samples, 
which were stored at the Wales Cancer Bank.
Sections of the formalin-ﬁ xed, paraﬃ  n-embedded 
tumour blocks were stained with haematoxylin and 
eosin, optical images were stored, and tumour 
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material was macrodissected, cored, or laser-capture 
microdissected for the DNA analyses. Tissue micro-
arrays were constructed for immunohistochemical 
analysis of EGFR. DNA was extracted with QIAmp 
DNA Microkits (Qiagen, Hilden, Germany). KRAS 
mutations in codons 12, 13, and 61 and BRAF mutations 
in codon 600 were screened with pyrosequencing. 
Additionally, KRAS (all three codons), BRAF 
(codons 594 and 600), and NRAS (codons 12 and 61) 
mutations were screened with MALDI-TOF mass array 
(Sequenom, San Diego, CA, USA).7 For KRAS, more 
than 1000 samples were successfully analysed by both 
techniques with greater than 99% genotype call 
concordance, and for BRAF more than 850 samples 
were analysed by both methods and greater than 98% 
of genotype calls were consistent. For discordant 
genotype calls, Sanger sequencing was used to establish 
genotype (webappendix p 1–3).
EGFR immunohistochemistry analysis was done on 
triplicate 0·6 mm cores in 25 tissue microarrays with 
validated control tissues stained with the standard US 
Food and Drug Administration approved EGFR pharmDx 
assay (DAKO, Glostrup, Denmark) at the University 
College London advanced diagnostics reference laboratory 
(London, UK). The cutoﬀ  points examined for positive 
versus negative tumours were 0 versus the rest, less than 
10% versus 10% or more, and less than 20% versus 20% 
or more of total tumour cells showing membrane 
staining (webappendix p 3).
The original objective was to establish whether the 
addition of cetuximab improved overall survival in 
patients with advanced colorectal cancer. However, 
shortly after COIN completed recruitment, external 
evidence showed that anti-EGFR antibodies were 
unlikely to beneﬁ t patients with this disease whose 
tumours carry KRAS mutations.5,6 The decision was 
Figure 1: Trial proﬁ le
EGFR=epidermal growth factor receptor.
Patients with advanced colorectal cancer, measurable disease,
ﬁt for chemotherapy, no previous EGFR immunohistochemistry
2445 consented
815 assigned
to arm A
815 assigned
to arm B
815 assigned
to arm C
Intermittent
therapy8
167 sample not
available
648 sample
available
668 sample
available
147 sample not
available
573 BRAF wild type
57 BRAF mutant
613 NRAS wild type
18 NRAS mutant
13 test failed 268 KRAS
mutant
367 KRAS
wild type
362 KRAS
wild type
297 KRAS
mutant
9 test failed 616 BRAF wild type
45 BRAF mutant
627 NRAS wild type
32 NRAS mutant
9 did not start
therapy
358 started
therapy
357 started
therapy
5 did not start
therapy
165 received full dose
67 received reduced dose
232 capecitabine-
based
126 ﬂuorouracil-
based
117 ﬂuorouracil-
based
240 capecitabine-
based
176 received full dose
64 received reduced dose
249 died
229 colorectal cancer
5 treatment-related
13 other
2 unknown
33 no data received 
for ≥6 months
26 no data received 
for ≥6 months
76 on follow-up 78 on follow-up 253 died
230 colorectal cancer
3 treatment-related
17 other
3 unknown
See Online for webappendix
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taken to revise the primary research hypothesis before 
any analysis was done and before KRAS mutation data 
for COIN patients became available. The revised 
statistical plan was reviewed and approved by the 
independent data monitoring committee and indepen-
dent trial steering committee. The revised primary 
objective thus became to determine whether the addition 
of cetuximab to continuous chemotherapy resulted in 
improved overall survival in patients with KRAS wild-
type tumours. The secondary objectives were to evaluate 
whether the research intervention resulted in improved 
overall survival in four groups: (1) patients with tumours 
wild-type for all of KRAS, BRAF, and NRAS; (2) patients 
with KRAS mutant tumours; (3) patients with tumours 
mutant for any of KRAS, BRAF, or NRAS; and (4) all 
patients randomly allocated to treatment groups. 
Progression-free survival, response, and toxic eﬀ ects 
were all evaluated in each of these patient groups. At the 
time of analysis for both overall and progression-free 
survival, survivors were censored at the date they were 
last known to be alive.
Statistical analysis
Originally the sample size for the arm B versus A 
comparison was 1614 patients, 807 in each group to parallel 
the arm C versus A comparison (see protocol for details of 
All patients KRAS wild-type group KRAS mutant group
Arm A (N=815) Arm B (N=815) Arm A (N=367) Arm B (N=362) Arm A (N=268) Arm B (N=297)
Sex
Male 525 (64%) 543 (67%) 245 (67%) 253 (70%) 169 (63%) 192 (65%)
Female 290 (36%) 272 (33%) 122 (33%) 109 (30%) 99 (37%) 105 (35%)
Age
Median (years) 63 (56–69) 63 (58–70) 63 (56–69) 64 (59–70) 63 (56–69) 64 (58–70)
>75 years 74 (9%) 72 (9%) 31 (8%) 30 (8%) 28 (10%) 27 (9%)
WHO performance status
0 375 (46%) 376 (46%) 177 (48%) 171 (47%) 114 (43%) 135 (45%)
1 378 (46%) 377 (46%) 166 (45%) 171 (47%) 131 (49%) 135 (45%)
2 62 (8%) 62 (8%) 24 (7%) 20 (6%) 23 (9%) 27 (9%)
Site of primary tumour
Colon 453 (56%) 444 (54%) 210 (57%) 197 (54%) 145 (54%) 163 (55%)
Rectum 243 (30%) 262 (32%) 101 (28%) 119 (33%) 90 (34%) 93 (31%)
Rectosigmoid junction 113 (14%) 106 (13%) 56 (15%) 46 (13%) 32 (12%) 41 (14%)
Status of primary tumour
Resected 445 (55%) 420 (52%) 218 (59%) 188 (52%) 157 (59%) 173 (58%)
Unresected 331 (41%) 346 (42%) 131 (36%) 148 (41%) 97 (36%) 107 (36%)
Local recurrence 39 (5%) 49 (6%) 18 (5%) 26 (7%) 14 (5%) 17 (6%)
Timing of metastases
Metachronous 249 (31%) 239 (29%) 125 (34%) 112 (31%) 84 (31%) 85 (29%)
Synchronous 552 (68%) 569 (70%) 236 (64%) 246 (68%) 180 (67%) 212 (71%)
No metastases 7 (1%) 6 (1%) 4 (1%) 5 (1%) 3 (1%) 0
Type of metastases
Liver only 174 (21%) 194 (24%) 91 (25%) 87 (24%) 44 (16%) 74 (25%)
Liver plus others 436 (53%) 418 (51%) 180 (49%) 190 (52%) 151 (56%) 155 (52%)
Non-liver 198 (24%) 197 (24%) 92 (25%) 80 (22%) 70 (26%) 68 (23%)
Number of metastatic sites
1 283 (35%) 305 (37%) 140 (38%) 131 (36%) 82 (31%) 113 (38%)
2 326 (40%) 311 (38%) 140 (38%) 139 (38%) 116 (43%) 115 (39%)
>2 199 (24%) 193 (24%) 83 (23%) 87 (24%) 87 (32%) 69 (23%)
Previous treatment for metastases
Radiotherapy 26 (3%) 24 (3%) 10 (3%) 9 (2%) 7 (3%) 12 (4%)
Surgery 142 (17%) 130 (16%) 64 (17%) 57 (16%) 55 (21%) 52 (18%)
Alkaline phosphatase <300 U/L 670 (82%) 696 (85%) 309 (84%) 309 (85%) 224 (84%) 257 (87%)
Platelet count <400 000 per μL 564 (69%) 549 (67%) 259 (71%) 251 (69%) 189 (71%) 189 (64%)
White blood cell count <10 000 per L 577 (71%) 574 (70%) 265 (72%) 252 (70%) 199 (74%) 217 (73%)
Data are n (%) or median (IQR). 
Table 1: Baseline characteristics for all patients and by KRAS mutation status
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arm C vs A sample size calculation). With 1614 patients, a 
6·4% advantage in overall survival at 2 years (from 20% to 
26·4%; hazard ratio [HR] 0·828) could be detected with 
90% power. When the primary objective of the arm B 
versus A comparison was prospectively revised to focus on 
the KRAS wild-type population, the primary analysis of 
arm A versus B was planned to take place when 511 overall 
survival events had occurred in patients with KRAS wild-
type tumours. In this molecularly selected cohort, a higher 
HR of 0·76 could be detected at 87% power with a two-
sided α of 0·05.
Analyses were undertaken according to a predeﬁ ned 
statistical analysis plan, which was approved in advance 
by the COIN trial management group before the database 
was locked (Sept 2, 2009). All patients randomly assigned 
to treatment group were included in the analyses, on the 
basis of the intention-to-treat principle. All p values are 
two-sided and were not adjusted for multiple testing. 
Time-to-event curves for analysis of overall and 
progression-free survival were estimated with the 
Kaplan-Meier method. HRs, conﬁ dence intervals, and 
p values were estimated with the log-rank method.
We compared worst toxic eﬀ ects experienced overall 
between treatment groups using a χ² test, or Fisher’s 
exact test in case of low event rates (n<5). Exploratory 
analyses to identify predictive factors were done with a 
Cox proportional hazards model entering treatment 
group, the potential predictive factor, and a treatment-
predictive factor interaction term. Interaction tests were 
done with likelihood-ratio tests of the null hypothesis 
that the interaction coeﬃ  cient is zero. Stata (version 11.1) 
was used for all analyses.
The trial is registered, ISRCTN27286448.
Role of the funding source
The trial was conceived and developed by the National 
Cancer Research Institute advanced colorectal clinical 
studies group. The MRC was the overall sponsor of the 
study, with some responsibilities for the sites in Ireland 
delegated to the Irish Clinical Oncology Research Group. 
Figure 2: Kaplan-Meier overall survival curves for patients with (A) KRAS wild-type, (B) KRAS mutant, (C) BRAF mutant and KRAS wild-type, and (D) KRAS, 
NRAS, and BRAF all wild-type tumours
HR=hazard ratio.
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The MRC, through its employees in the MRC Clinical 
Trials Unit, are authors on the paper and were integral 
to the collection and analysis of the paper and the 
writing of the report. The corresponding author had full 
access to the data and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Between March 9, 2005, and May 9, 2008, 2445 patients 
were randomly assigned to treatment groups at 111 centres 
in the UK and Ireland, of whom 1630 patients were 
assigned to the arm A versus B comparison (ﬁ gure 1). 
Their baseline characteristics are shown in table 1 and 
were well balanced between the two trial groups and across 
the diﬀ erent subgroups deﬁ ned by KRAS mutation status.
Samples from 1316 (81%) patients were suitable for 
analysis of KRAS, BRAF, and NRAS mutation status 
(samples from 141 patients [9%] were not available and 
173 [11%] samples contained insuﬃ  cient tumour material 
for processing). Mutations were detected in KRAS in 
565 (43%) patients, BRAF in 102 (8%), and NRAS in 
50 (4%) with greater than 98% success rates (webappen-
dix p 3). Figure 1 shows the full results by mutation site 
and by trial group. 706 (54%) patients carried a KRAS, 
BRAF, or NRAS mutation (no patients had KRAS and 
BRAF mutations or BRAF and NRAS mutations, and 
11 patients carried both KRAS and NRAS mutations) and 
581 (44%) patients were all wild type.
37 patients (2%) did not start trial therapy because of 
clinical deterioration after randomisation, patient choice, 
or because they were subsequently found to be ineligible. 
Figure 1 shows choice of chemotherapy (capecitabine-
based or ﬂ uorouracil-based). 153 (19%) patients in the 
cetuximab group (arm B) started therapy with the lower 
dose of capecitabine of 850 mg/m². The median duration 
of follow-up among surviving patients with KRAS wild-
type tumours randomly assigned to the control group 
was 21 months (IQR 18–29) and to the cetuximab 
group was 23 months (17–29), and was similar for the 
whole population.
At the time of analysis, there was no evidence of a 
diﬀ erence in overall survival between treatment groups. 
257 (71%) patients with KRAS wild-type tumours had 
died in each group, with a median survival of 17·9 months 
(IQR 10·3–29·2) in the control group and 17·0 months 
(9·4–30·1) in the cetuximab group (HR 1·04, 95% CI 
0·87–1·23; p=0·67; ﬁ gure 2). Of these deaths, 467 (90·9%) 
were due to colorectal cancer, eight (1·6%) were 
treatment-related, 32 (6·2%) were due to other causes, 
and the causes for seven (1·4%) are still unknown. There 
was no evidence of an eﬀ ect of the addition of cetuximab 
to oxaliplatin-based chemotherapy on overall survival in 
any of the prespeciﬁ ed cohorts—eg, median survival in 
patients with KRAS mutant tumours was 14·8 months 
(IQR 9·5–22·8) in the control group and 13·6 months 
(8·0–26·1) in the cetuximab group (HR 0·98, 95% CI 
0·81–1·17, p=0·80; ﬁ gure 2, webappendix p 7).
We noted no evidence of an eﬀ ect of cetuximab on the 
risk of progression in the KRAS wild-type group (median 
progression-free survival was 8·6 months in both groups, 
IQR 5·0–12·5 in the control group, 5·1–13·8 in the 
cetuximab group; HR 0·96, 95% CI 0·82–1·12, p=0·60; 
webappendix p 8). No evidence of a diﬀ erence in 
progression-free survival was seen among all patients 
nor in any of the genetically deﬁ ned groups. In COIN, 
110 patients had the KRAS Gly13Asp mutation that was 
recently reported13 to correlate with some beneﬁ t from 
the addition of cetuximab in chemorefractory patients. In 
these 110 patients, the HR for eﬀ ect of cetuximab on 
progression-free survival was 1·11 (95% CI 0·76–1·63, 
p=0·60), compared with an HR of 1·05 (0·87–1·27, 
p=0·61) in patients with other KRAS mutations. In those 
treated with infusional ﬂ uorouracil, 30 patients had 
KRAS Gly13Asp mutations and the HR was 1·07 (95% CI 
Figure 3: Tumour mutational status as a prognostic factor for overall survival
HR=hazard ratio.
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0·51–2·24, p=0·86) compared with 1·03 (0·74–1·44, 
p=0·85) in patients with other KRAS mutations.
Irrespective of treatment received, median overall 
survival was shorter in patients who had mutations in any 
of the three oncogenes (n=706, 13·6 months, 
IQR 7·9–23·1) than among those whose tumours were 
wild type for all of KRAS, NRAS, and BRAF (n=581, 
20·1 months, IQR 11·5–31·7; log-rank test p<0·0001, 
ﬁ gure 3). If the mutational type was then segregated, 
median overall survival was shorter in patients whose 
tumours had mutations in BRAF (n=102, 8·8 months, 
IQR 4·5–16·1) than in those with BRAF wild-type tumours 
but a mutation in KRAS (n=548, 14·4 months, 8·5–24·0) 
or NRAS (n=38, 13·8 months, 8·2–24·1). A global test for 
diﬀ erences was highly signiﬁ cant (p<0·0001), as was a 
test for trend (p<0·0001, ﬁ gure 3). The overall survival for 
the primary analysis cohort, patients with KRAS wild-type 
tumours, was 17·5 months (n=729, IQR 9·6–30·3). This 
group is not shown in either ﬁ gure because it contains 
prognostically mixed cohorts—ie, it also includes some 
patients with BRAF and NRAS mutant tumours.
A prognostic eﬀ ect of patients’ tumour mutation status 
was also noted on progression-free survival, with median 
progression-free survival ranging from 5·6 months 
(IQR 2·8–8·6) for patients with BRAF mutant tumours 
to 9·0 months (5·7–14·1) for those tumours wild type for 
all of KRAS, NRAS, and BRAF. These eﬀ ects remained 
strongly signiﬁ cant when added into a multivariate 
model adjusted for other important prognostic variables. 
For progression-free survival, all three mutations 
remained independently signiﬁ cant (p<0·0001, p<0·0001, 
and p=0·0088 for KRAS, BRAF, and NRAS, respectively), 
whereas for overall survival, KRAS and BRAF remained 
signiﬁ cant (p<0·0001 for both), but NRAS did not 
(p=0·15). Among the other variables in the multivariate 
model were the four prognostic indicators suggested by 
Köhne and colleagues13—ie, white blood cell count, 
number of metastatic sites, alkaline phosphatase, and 
WHO performance status. For both overall and 
progression-free survival, all four remained independently 
signiﬁ cant at the 5% level.
An agreed score for EGFR immunohistochemistry was 
available for 1065 (65%) patients. Reasons for 
unavailability of scores included no tissue block received, 
no satisfactory score achievable, and tissue regarded as 
unsatisfactory for analysis by immunohistochemistry. 
The cutoﬀ  point of less than 10% versus 10% or more of 
cells showing EGFR membrane staining was selected as 
being the most reproducible and widely used index for 
scoring of EGFR positivity. This approach identiﬁ ed 310 
(58%) of 533 patients in the control group and 329 (62%) 
of 532 patients in the cetuximab group as having EGFR-
positive tumours. Positive EGFR immunohistochemistry 
was a poor prognostic factor in the KRAS wild-type cohort 
(for progression-free survival, HR 1·27, 95% CI 1·07–1·52, 
p=0·0078 in univariate analysis and HR 1·25, 1·05–1·50, 
p=0·015 after adjustment for prognostic factors found to 
be signiﬁ cant for progression-free survival in a separate 
Arm A Arm B p value for A vs B
Fluorouracil-
based therapy 
(N=279)
Capecitabine-
based therapy 
(N=536)
p value Fluorouracil-
based therapy 
(N=281)
Capecitabine-
based therapy 
(N=534)
p value Fluorouracil-
based therapy
Capecitabine-
based therapy
Platelet count 7 (3%) 16 (3%) 0·70 7 (2%) 16 (3%)  0·68  0·99  0·99
Haemoglobin 6 (2%) 7 (1%)  0·36 21 (7%) 17 (3%)  0·0058*  0·0033†  0·038†
White blood cell count 28 (10%) 6 (1%)  0·0001* 33 (12%) 3 (1%)  0·0001*  0·52  0·32
Neutrophil count 86 (31%) 21 (4%)  0·0001* 88 (31%) 13 (2%)  0·0001*  0·90  0·17
Nausea 13 (5%) 37 (7%)  0·21 17 (6%) 48 (9%)  0·14  0·58  0·21
Vomiting 10 (4%) 27 (5%)  0·34 18 (6%) 38 (7%)  0·70  0·17  0·16
Diarrhoea 31 (11%) 82 (15%)  0·10 55 (20%) 141 (26%)  0·030†  0·0055†  0·0001†
Hand–foot syndrome 7 (3%) 25(5%)  0·13 18 (6%) 67 (13%)  0·0064†  0·026†  0·0001†
Nail changes 0 0 ·· 6 (2%) 11(2%)  0·94  0·014†  0·00045†
Skin rash 0 1 (<1%)  0·99 56 (20%) 108 (20%)  0·92  0·0001†  0·0001†
Peripheral neuropathy 63 (23%) 86 (16%)  0·022* 38 (14%) 73 (14%)  0·95  0·0053*  0·28
Hypomagnesaemia 0 0 ·· 16 (6%) 16 (3%)  0·059  0·0001†  0·0001†
Anorexia 12 (4%) 31 (6%)  0·37 28 (10%) 43 (8%)  0·36  0·014†  0·14
Alopecia 1 (<1%) 2 (<1%)  0·99 0 1 (<1%)  0·99  0·32  0·57
Pain 34 (12%) 75 (14%)  0·47 34 (12%) 72 (13%)  0·58  0·98  0·81
Stomatitis 13 (5%) 4 (1%)  0·00040* 27 (10%) 18 (3%)  0·00021*  0·023†  0·0023†
Lethargy 51 (18%) 98 (18%)  0·99 81 (29%) 128 (24%)  0·13  0·0033†  0·023†
Vein pain 0 8 (1%)  0·056 0 3 (1%)  0·56 ··  0·13
Data are n (%) or p value. *More toxic eﬀ ects in arm A than in arm B, or in patients on ﬂ uorouracil-based therapy than on capecitabine-based therapy (p<0·05). †More toxic 
eﬀ ects in arm B than arm A, or on capecitabine-based therapy than on ﬂ uorouracil-based therapy (p<0·05).
Table 2: Grade 3 or higher toxic eﬀ ects in all patients randomly assigned to treatment groups, by chemotherapy regimen over entire treatment period
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analysis using a backwards stepwise procedure). In the 
KRAS wild-type cohort, there was no evidence of a 
predictive eﬀ ect of EGFR immunohistochemistry 
irrespective of cutoﬀ  point. However, in the KRAS mutant 
cohort, patients with more than 10% of tumour cells 
EGFR positive had a detrimental eﬀ ect on progression-
free survival from the addition of cetuximab (HR 1·28, 
95% CI 1·00–1·63, p=0·047, n=285). By contrast, no such 
eﬀ ect was identiﬁ ed in the EGFR less than 10% cohort 
(HR 0·87, 0·64–1·19, p=0·37, n=169).
A complete or partial response was reported in 209 
(57%) KRAS wild-type patients in the control group and 
in 232 (64%) KRAS wild-type patients receiving 
cetuximab (OR 1·35, 95% CI 1·00–1·82, p=0·049). The 
addition of cetuximab resulted in reduced dose intensity 
in KRAS wild-type patients over the ﬁ rst 24 weeks (for 
ﬂ uorouracil-based therapy: median 78% in the control 
group [IQR 70–87] vs 73% [66–82] in the cetuximab 
group, p=0·031; for capecitabine-based therapy: 85% 
[74–92] vs 79% [67–88], p=0·0021). In patients receiving 
ﬂ uorouracil-based therapy, this diﬀ erence was noted 
mainly in the dose intensity of infused ﬂ uorouracil 
(p=0·02; webappendix p 4). In those receiving 
capecitabine-based therapy, dose intensity was diﬀ erent 
for both oxaliplatin and capecitabine, but these 
diﬀ erences largely disappeared after the capecitabine 
dose reduction in arm B.
The addition of cetuximab (arm B) did not have a 
noticeable eﬀ ect on time on treatment in either the 
capecitabine-based or ﬂ uorouracil-based therapy groups. 
In both arms combined, the overall median duration of 
treatment was 29 weeks (IQR 16–41) in patients receiving 
ﬂ uorouracil-based therapy, but 25 weeks (IQR 13–35) in 
those given capecitabine-based therapy (p=0·0028 
adjusting for treatment group; webappendix p 4).
Addition of cetuximab increased the incidence of skin 
(rash, nail changes, and hand–foot syndrome), 
gastrointestinal (diarrhoea, stomatitis), and other toxic 
eﬀ ects (anaemia, lethargy, and hypomagnesaemia; 
table 2). In both treatment groups there were increased 
toxic eﬀ ects with  ﬂ uorouracil-based therapy for 
neutropenia, peripheral neuropathy, and stomatitis 
compared with the patients on capecitabine-based 
therapy. With the addition of cetuximab (arm B), 
diarrhoea and skin toxic eﬀ ects were reported more 
often in patients on capecitabine-based therapy than on 
ﬂ uorouracil-based therapy, and peripheral neuropathy 
was less common in patients treated with ﬂ uorouracil-
based therapy. In the KRAS wild-type cohort, similar 
diﬀ erences in toxic eﬀ ects were noted, but were not 
statistically signiﬁ cant (webappendix p 5). After the dose 
reduction in the subgroup of patients receiving 
capecitabine-based therapy and cetuximab,9 the 
incidence of grade 3 or higher diarrhoea fell from 30% 
(116/381; p<0·0001 vs no cetuximab) to 16% (25/153; 
p=0·25 vs no cetuximab). Other toxic eﬀ ects were also 
lowered (data not shown).
Among all patients randomly assigned to treatment 
groups, treatment-related deaths were reported in ten 
patients in the control group and nine in the cetuximab 
group. Of the nine patients taking cetuximab, eight were 
in the capecitabine-based therapy plus cetuximab 
subgroup. Seven of the deaths occurred before the 
capecitabine dose reduction and were predominantly 
related to gastrointestinal toxic eﬀ ects. In the control 
group, the ten deaths were split evenly between 
capecitabine-based and ﬂ uorouracil-based therapy, with 
no pattern to the causative toxic eﬀ ects noted.
16 additional factors were explored for predictive value 
of progression-free survival among the all-wild-type 
patients, because this subset was judged the most likely 
to be responsive. Improved progression-free survival 
with cetuximab was seen in patients treated with 
ﬂ uorouracil-based therapy (HR 0·72, 95% CI 0·53–0·98, 
p=0·037), but not in those treated with capecitabine-
based therapy (HR 1·02, 0·82–1·26, p=0·88; p=0·10 for 
interaction; see webappendix p 9 for data for KRAS wild-
type patients). Additionally, patients with no or one 
metastatic site had improved progression-free survival 
with cetuximab (HR 0·73, 0·55–0·97, p=0·030) whereas 
those with two or more metastatic sites did not (HR 1·07, 
0·86–1·33, p=0·56; p=0·036 for interaction; ﬁ gure 4). 
Figure 4: Exploratory predictive factor analyses
HR=hazard ratio.
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Similar results were obtained for patients with liver 
metastases only versus more widespread metastatic 
disease. Further analyses showed that both number of 
metastatic sites or liver-only metastases and choice of 
ﬂ uoropyrimidine therapy had signiﬁ cant (at the 10% level) 
interactions with treatment group. Fluoropyrimidine 
therapy was the weaker of the two, but neither was 
substantially aﬀ ected by adjustment for important 
prognostic factors, or for each other. Thus, progression-
free survival beneﬁ t was restricted to patients with KRAS 
wild-type tumours and zero or one metastatic site treated 
with ﬂ uorouracil-based therapy (n=96, HR 0·55, 95% CI 
0·35–0·87, p=0·011).
In analysis of surgery for metastases, no increase in 
potentially curative liver resections was identiﬁ ed, with 
resection rates among KRAS wild-type patients who had 
liver-only metastases at baseline of 13% (n=12/91) in the 
control group and 15% (n=13/87) in the cetuximab group 
(p=0·74). At the time of analysis, second-line therapy was 
administered to signiﬁ cantly fewer patients in the 
cetuximab group (386 [56%] of 695) than in the control 
group (448 [62%] of 724; p=0·015) in patients who were 
eligible to receive further treatment (patients who were 
alive, had completed COIN protocol treatment, and were 
not lost to follow-up). Patients treated with ﬂ uorouracil-
based rather than capecitabine-based therapy were also 
more likely to receive second-line therapy (table 3).
Discussion
COIN is the largest trial of the addition of an EGFR-
targeted monoclonal antibody to ﬁ rst-line combination 
chemotherapy in patients with advanced colorectal 
cancer. No beneﬁ t could be shown with the addition of 
cetuximab to oxaliplatin-based chemotherapy. This 
ﬁ nding holds true both for the primary outcome measure 
of overall survival and for the secondary outcome 
measure of progression-free survival for the KRAS wild-
type cohort. In a predeﬁ ned secondary analysis, we 
postulated that the group of patients with no mutation in 
the genes tested within the RAS–RAF–MAP kinase 
pathway would be the most likely to show a beneﬁ t. 
However, even patients with tumours wild type for all 
three genes did not show any evidence of a beneﬁ t from 
the addition of cetuximab. Conversely, we have recorded 
no evidence of a detrimental eﬀ ect for patients with 
KRAS mutant tumours. De Roock and colleagues14 have 
suggested that the KRAS Gly13Asp mutation might not 
predict lack of beneﬁ t with use of EGFR inhibitors. In 
COIN, this mutation was identiﬁ ed in 110 patients, but 
was not associated with any diﬀ erence in outcome with 
the addition of cetuximab. We do, however, show that 
these mutations have a strong prognostic eﬀ ect, with 
median survival ranging from 8·8 months for patients 
with BRAF mutant tumours, about 14 months for patients 
with KRAS or NRAS mutant tumours, to 20·1 months 
for patients with tumours that were all wild type. These 
factors remain strongly prognostic in a multivariate 
analysis, and consideration should therefore be given in 
future trials to their use as stratiﬁ cation factors or 
inclusion or exclusion criteria.
The overall survival of patients in COIN was inferior to 
other trials of similar design in this setting for 
chemotherapy versus chemotherapy plus anti-EGFR 
therapy.15–22 Evidence that patients with colorectal cancer 
in the UK (and Denmark) have 5–10% inferior survival 
compared with patients from Canada, Australia, and 
Scandinavia has recently been published.23 This eﬀ ect 
was ascribed to more advanced disease stage at 
presentation, reﬂ ected especially in inferior 1-year 
survival. In COIN, the patients were drawn from 
111 hospitals across the UK and Ireland and thus are 
more broadly representative of patients with advanced 
colorectal cancer than are those in other trials in which 
recruitment is from more selected centres. The COIN 
trial was not intended for patients who receive ﬁ rst-line 
chemotherapy in anticipation of possible resection of 
metastases, and the trial cohort therefore had fairly 
advanced disease with a substantial proportion of patients 
having unresected primary tumours and synchronous 
Arm A Arm B p value
All KRAS wild-type patients
Total eligible for second-line therapy* 323 311 ··
Therapy received
Any second-line therapy 210 (65%) 169 (54%)  0·0061
Irinotecan 171 (53%) 132 (42%)  0·0082
Fluoropyrimidine 155 (48%) 121 (39%)  0·021
Oxaliplatin 60 (19%) 46 (15%)  0·20
EGFR-targeted therapy 16 (5%) 21 (7%)  0·33
Other therapy 10 (3%) 8 (3%)  0·69
Patients receiving ﬂ uorouracil-based therapy
Total eligible for second-line therapy* 113 98 ··
Therapy received
Any second-line therapy 78 (69%) 53 (54%)  0·026
Irinotecan 65 (58%) 40 (41%)  0·015
Fluoropyrimidine 68 (60%) 44 (45%)  0·027
Oxaliplatin 22 (19%) 14 (14%)  0·32
EGFR-targeted therapy 7 (6%) 5 (5%)  0·78
Other therapy 2 (2%) 1 (1%)  0·99
Patients receiving capecitabine-based therapy
Total eligible for second-line therapy* 210 213 ··
Therapy received
Any second-line therapy 132 (63%) 116 (54%)  0·080
Irinotecan 106 (50%) 92 (43%)  0·13
Fluoropyrimidine 87 (41%) 77 (36%)  0·27
Oxaliplatin 38 (18%) 32 (15%)  0·40
EGFR-targeted therapy 9 (4%) 16 (8%)  0·16
Other therapy 8 (4%) 7 (3%)  0·77
Data are n (%) or p value. EGFR=epidermal growth factor receptor. *Patients deemed eligible for second-line therapy 
were those that survived at least 14 days after coming oﬀ -trial.
Table 3: Second-line therapy received by KRAS wild-type patients, by chemotherapy received
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metastatic disease. These factors aﬀ ect survival in the 
control group as well as the experimental group. However, 
the characteristics of the population were not 
fundamentally diﬀ erent from those in other trials of 
EGFR-targeted antibodies so, although contributing to 
the shorter overall survival, they do not adequately 
account for the failure to detect the expected improvement 
with addition of cetuximab. Less aggressive use of 
eﬀ ective treatments has been a criticism of the UK health 
system. However, combination chemotherapy with or 
without cetuximab used until disease progression is 
thought to be aggressive ﬁ rst-line therapy. The fact that 
bevacizumab is not approved for reimbursement in the 
UK National Health Service means that the small increase 
in overall survival from the use of this agent will not be 
reﬂ ected in the survival of COIN patients. A signiﬁ cant 
reduction in the use of second-line therapy was also 
noted in the cetuximab group (56% vs 62%). This ﬁ nding 
could be a consequence of the increased toxic eﬀ ects 
noted with addition of cetuximab, but by itself is unlikely 
to account for the absence of survival beneﬁ t in view of 
the lack of overall beneﬁ t in progression-free survival and 
the small diﬀ erence shown.
One major factor that could aﬀ ect the beneﬁ t of the 
addition of cetuximab to chemotherapy is the precise 
nature of the agents used in combination. The addition of 
bevacizumab to cetuximab and combination chemo-
therapy seems to be detrimental.15,16 The only phase 3 trial 
in ﬁ rst-line therapy showing an overall survival beneﬁ t to 
date used irinotecan and infusional ﬂ uorouracil as the 
chemotherapy backbone.17 By comparison, the trials using 
oxaliplatin have not shown improved overall survival and 
this failure has raised the possibility of a negative 
interaction between oxaliplatin and cetuximab.19–21
A broad set of predeﬁ ned exploratory analyses have 
been done in an attempt to understand the results of the 
COIN trial. The only group for which some evidence of a 
potential beneﬁ t was suggested were those patients who 
have three coincident factors: KRAS wild-type tumours, 
treatment with infused ﬂ uorouracil rather than 
capecitabine, and a limited distribution of metastatic 
disease (either zero or one metastatic site vs two or more 
sites, or liver metastases only vs more widespread 
disease). This cohort generally conforms to those patients 
identiﬁ ed in guidance from the UK National Institute for 
Health and Clinical Excellence for the use of cetuximab, 
which was issued shortly before the trial was analysed.24 
For patients with KRAS wild-type tumours treated with 
infused ﬂ uorouracil, the beneﬁ t in progression-free 
survival (HR for ﬂ uorouracil-based therapy was 0·77, 
p=0·06, compared with HR for capecitabine-based 
therapy of 1·06, p=0·56, p for interaction 0·07; 
webappendix p 9) was consistent with other trials.15–22 
This ﬁ nding again suggests the potential importance of 
the agents used in combination when using EGFR-
targeted therapies.
Within the COIN trial, after identiﬁ cation of increased 
toxic eﬀ ects in patients treated with capecitabine, 
oxaliplatin, and cetuximab, a capecitabine dose reduction 
was mandated in the cetuximab group only.9 This change 
successfully reduced levels of toxic eﬀ ects to rates similar 
to those in the control group and improved the dose of 
oxaliplatin delivered, but obviously reduced the exposure 
of those 19% of patients in arm B to ﬂ uoropyrimidine. 
The lack of beneﬁ t in patients treated with capecitabine 
could be accounted for at least in part by the increase in 
toxic eﬀ ects recorded, and the resulting reduction in dose 
intensity of the chemotherapy administered or by other 
undetermined factors. However, we emphasise that these 
subgroup ﬁ ndings need validation.
This trial was one of the ﬁ rst not to require positive 
EGFR immunohistochemistry as a patient selection 
characteristic. 22% of patients were completely negative 
and 40% had less than 10% EGFR membrane staining. 
In COIN, there is no evidence to suggest that EGFR 
immunohistochemistry staining is a predictive factor for 
clinical beneﬁ t of the addition of cetuximab in the KRAS 
wild-type population. This ﬁ nding does not support the 
requirement for EGFR testing in the current cetuximab 
licence. Outcomes in patients with KRAS mutant 
tumours were heterogeneous with respect to EGFR 
staining, such that those with greater than 10% EGFR 
staining experienced a detrimental eﬀ ect on addition of 
cetuximab as shown in some other studies,17 but this 
eﬀ ect was not recorded in patients with less than 
10% EGFR staining.
The results of the COIN trial are unexpected and add to 
the variance seen in other trials evaluating the use of 
EGFR monoclonal antibodies in combination with 
Panel: Research in context
Systematic review
Several phase 3 trials have assessed the beneﬁ t of the addition 
of epidermal-growth-factor-receptor-targeted therapies to 
standard therapy for advanced colorectal cancer with varying 
results.5,6,15–18,20,21 Systematic review suggests that this therapy is 
associated with improved progression-free survival, but with 
the greatest advantage seen in patients who have received 
previous chemotherapy. The beneﬁ ts are conﬁ ned to patients 
with no evidence of mutation in the KRAS oncogene.
Interpretation
The outcome of this study is contrary to expectation showing 
no beneﬁ t from the addition of cetuximab in patients with 
KRAS wild-type tumours. There is an interaction with the 
choice of chemotherapy used, such that patients choosing 
the oral ﬂ uorouracil prodrug capecitabine plus oxaliplatin 
gained no beneﬁ t in any subgroup. This ﬁ nding could be 
attributable to overlapping gastrointestinal toxic eﬀ ects and 
as a result this triple combination cannot be recommended. 
By contrast, the results with infusional ﬂ uorouracil plus 
oxaliplatin treatment mirrored those of other studies 
showing a small beneﬁ t with the addition of cetuximab.
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chemotherapy in the ﬁ rst-line treatment of advanced 
colorectal cancer (panel). The overall lack of beneﬁ t of 
the addition of cetuximab to oxaliplatin and 
ﬂ uoropyrimidine combinations seen in the COIN trial, 
even in the absence of bevacizumab, is likely to be 
attributable to the speciﬁ c toxic eﬀ ect proﬁ le of the 
combination of the oxaliplatin and capecitabine 
chemotherapy backbone, with which no beneﬁ t was seen 
in any subgroup when cetuximab was added. By contrast, 
in patients treated with oxaliplatin and infusional 
ﬂ uorouracil, similar beneﬁ ts in progression-free survival 
were seen as in other studies. The potent prognostic 
eﬀ ect of BRAF, KRAS, and NRAS mutations on the 
outcome of patients with advanced colorectal cancer 
shows the fundamental importance of these changes and 
emphasises the need to stratify future trials for these 
factors and to seek speciﬁ c therapeutic approaches within 
these molecular subgroups.
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